Lucitanib

Drug Profile

Lucitanib

Alternative Names: AL 3810; CO-3810; E-3810 - Ethical Oncology Science; S-80881

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Advenchen Laboratories
  • Developer Clovis Oncology; Servier; ShangHai HaiHe Pharmaceutical; Shanghai Institute of Materia Medica
  • Class Acetamides; Antineoplastics; Cyclopropanes; Naphthalenes; Phenyl ethers; Quinolines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Antioxidants; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors; Proto oncogene proteins c raf inhibitors; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Non-small cell lung cancer
  • Phase I Cancer
  • No development reported Solid tumours

Most Recent Events

  • 01 Nov 2016 Clovis Oncology and University of California, San Diego withdraw a phase II trial for Cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) prior to enrolment in USA (PO) (NCT02747797)
  • 01 Sep 2016 Clovis Oncology completes a phase II trial for Non-small cell lung cancer (Metastatic disease, Second-line or greater therapy) in USA, France, Germany, Italy and Spain (NCT02109016)
  • 20 Jul 2016 Phase-I clinical trials in Cancer in China (PO) (Advenchen Laboratories pipeline, July 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top